MedTrace Logo

Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia

NCT05050890 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2021-09-30

No results posted yet for this study

Summary

This is a cohort, single-center, prospective study that seeks to analyze the circulating tumor DNA (ctDNA) in patients diagnosed with breast cancer, who will undergo neoadjuvant treatment.

Conditions

  • Breast Neoplasm

Interventions

OTHER

ctDNA level during neoadjuvant chemotherapy

ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure

Sponsors & Collaborators

  • Instituto Brasileiro de Controle do Cancer

    lead OTHER

Principal Investigators

  • Camila Giro, MD · IBCC Oncologia

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2021-11-01
Completion
2022-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05050890 on ClinicalTrials.gov